Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desucumab for secondary osteoporosis in adults with ankylosing spondylitis
ChiCTR2400086783Phase 4Not yet recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of denosumab in osteoporosis and ankylosing spondylitis (AS) (3 arms), sponsored by Zhejiang Provincial People's Hospital. Primary endpoint: Bone mineral density. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosisankylosing spondylitis (AS)
Beyond the preview
Go deeper on ChiCTR2400086783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086783.